Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company specializing in endocrine diseases and tumors, revealed encouraging...
BRUKINSA is the first and only BTK inhibitor approved across five oncology indications and the first and only approved in follicular lymphoma Approv...
Debiopharm a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectiou...
“We are excited to commence patient enrollment for the PoC human clinical trial, marking a significant milestone in our mission to revolution...
23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, released three new genetic reports for 23andMe+ members on breast...
GMP material to be used in Phase Ib study in platinum-resistant ovarian cancer (PROC) patients scheduled to start this year. Previously reported Phase I sa...
FogPharma®, a clinical-stage biopharmaceutical company dedicated to delivering a new class of therapies that go beyond the limits of currently availabl...
The test is covered by Medicare and many commercial insurance plans for eligible patients Exact Sciences Corp., a leading provider of cancer scree...
Fresenius Kabi announced it has introduced Cyclophosphamide for Injection, USP, a generic substitute for Cytoxan, for use in treating several forms o...
Curve Therapeutics, a pioneering biotechnology firm, announced a significant £40.5 million Series A funding round, led by Pfizer Ventures and joined ...
Aleta Biotherapeutics (Aleta), a pioneer in immuno-oncology with a focus on CAR T-Cell Engager (CTE) platforms, in collaboration with Cancer Research UK&rs...
Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announced tha...
Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a pioneering oncology biopharmaceutical company, has revealed prom...
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have announced the acceptance of their Biologics License Application (BLA) for datopotamab...
© 2024 Biopharma Boardroom. All Rights Reserved.
